On March 21, 2025, Beijing WeMed Medical Technology Co., Ltd. announced that its ETcath Interventional Surgery Assistance System had received NMPA approval, according to WeMed — making it the first coronary interventional robot developed entirely within China to clear domestic regulatory review. The approval follows eight years of development and a prospective randomized controlled trial design that set a higher-than-typical evidence bar for a medical device submission.
Eight Years From Prototype to Approval
WeMed Medical was founded in 2014 by engineers with backgrounds in digital vascular imaging. The company’s focus was narrow from the start: build a complete, domestically owned technology stack for interventional cardiology, spanning imaging hardware, robotic manipulation, and AI-driven guidance.
Early development of what would become the ETcath system began around 2016–2017, with a first clinical proof-of-concept in October 2021 when Professor Zhou Yujie’s team at Beijing Anzhen Hospital performed China’s first PCI procedure using a domestically developed interventional robot, according to WeMed. The procedure covered the full PCI workflow — guidewire navigation, balloon catheter delivery, coronary stent implantation, and IVUS catheter positioning.
The path from that demonstration to NMPA approval took another three and a half years, shaped largely by the decision to pursue a prospective randomized controlled trial. Most Class III medical device approvals in China proceed through single-arm or retrospective study designs. WeMed’s choice of a prospective RCT — conducted across five Grade A tertiary hospitals — imposed a longer development timeline but generated a higher grade of clinical evidence. The company reported a 100% procedural success rate across the trial cohort, according to WeMed.
NMPA registration number for the ETcath was issued March 21, 2025.
What the Force-Feedback Sensor Actually Does
The technical feature that WeMed emphasized most in its approval communications was the force-feedback system. ETcath’s proprietary sensors can detect resistance as subtle as 0.01 newtons during catheter navigation, relaying tactile information back to the operating physician at the remote console, according to WeMed.
In manual PCI, an interventionalist’s tactile sense — the feel of a guidewire meeting resistance, threading through a tight stenosis, or contacting a vessel wall — is part of how experienced operators navigate complex coronary anatomy. Robotic systems that lack force feedback remove that sensory channel entirely, forcing operators to rely on fluoroscopic imaging alone. WeMed described its implementation as the first of its kind among interventional robots, though independent verification of competitive comparisons across all platforms globally has not been confirmed.
The implications are practical: operators working with ETcath can detect subtle changes in resistance that fluoroscopy alone might not reveal until a catheter has already moved past an optimal position or reached a vessel branch. The system’s motion accuracy is below 0.05 mm, and its integrated DSA imaging provides 0.1 mm lesion identification, according to WeMed’s published specifications.
Beyond navigation precision, ETcath addresses a well-documented occupational hazard: radiation exposure. Interventional cardiologists who perform high volumes of PCI spend years working in close proximity to X-ray sources while wearing lead aprons. The cumulative orthopedic and radiation exposure burden is substantial enough that it drives some physicians out of the specialty. ETcath’s remote console allows operators to work in standard clothing, away from the fluoroscopy field. WeMed did not publish specific radiation reduction figures in its approval communications.
What “Fully Domestic” Means
The “first fully domestic” designation matters because China’s coronary interventional robot market already had an approved platform when ETcath cleared review: the R-ONE system, distributed in China by CathBot.
CathBot is a joint venture formed in 2021 between MicroPort MedBot (51%) and French company Robocath S.A.S (49%). The R-ONE platform was originally developed and CE-certified in France, then brought to the Chinese market through the CathBot structure. It received NMPA approval in December 2023 and had entered active clinical use at five Shanghai hospitals by 2025.
The distinction WeMed draws is one of intellectual property origin. R-ONE’s core technology derives from Robocath’s French development program; CathBot localizes production and holds the China distribution rights, but the foundational IP and design originate outside China. ETcath, by contrast, was developed entirely within WeMed’s Beijing engineering organization. The company holds over 100 patents on ETcath technology, with the company reporting that 80% are invention patents.
This distinction carries practical weight in China’s medical device procurement environment. Hospital tenders for equipment in categories where domestic alternatives exist increasingly weigh domestic-origin IP favorably. Government procurement policies issued since 2020 have progressively tightened the criteria for what qualifies as a domestically developed product in high-value medical equipment categories.
The Eye-Hand-Brain Strategy
WeMed’s broader product thesis extends beyond any single device. The company operates what it calls an integrated “Eye-Hand-Brain” strategy, combining three product lines:
- Eye: WeMed’s Aurora DSA system, a 7-axis flat-panel digital subtraction angiography unit which WeMed describes as the first domestic high-end DSA to receive both NMPA and CE certification in 2020. The company’s imaging algorithms achieve 0.1 mm lesion identification accuracy, according to WeMed.
- Hand: The ETcath robotic system, acting as a remotely controlled bionic manipulator for catheter and guidewire operations.
- Brain: An AI imaging analysis platform providing real-time surgical guidance integrated with DSA data.
This vertical integration — from imaging hardware to robotic execution to AI guidance — distinguishes WeMed’s approach from companies that develop the robotic arm alone and integrate with third-party imaging. In practice, it means WeMed can configure a catheterization laboratory where all three systems share a unified data architecture and display environment, rather than requiring interface development across different vendors.
WeMed also acquired Italian mobile C-arm brand EC in 2016, establishing a dual-center development model between Beijing and Europe. That acquisition gave WeMed a manufacturing and sales presence in Europe over a decade before ETcath’s approval, and its C-arm products have been distributed in more than 20 countries.
Market Context
Coronary intervention in China is a large and growing clinical segment. Industry data puts annual coronary angioplasty procedures well above one million cases, with continued growth driven by the aging population and rising prevalence of cardiovascular risk factors. The interventional cardiology robot market, by contrast, is nascent: R-ONE entered clinical use only in 2023, and ETcath’s commercial launch comes in 2025.
Both platforms face a structural adoption challenge familiar to all surgical robot markets: procedural volume needs to be high enough to justify the capital cost, and reimbursement frameworks need to accommodate robot-assisted procedures. The NMPA’s Announcement No. 63, issued in July 2025, names surgical robots including interventional systems as a priority category for expedited lifecycle regulation — a policy signal that supports, but does not resolve, the reimbursement question.
For WeMed, commercial deployment now begins in earnest. In October 2025, the ETcath200 was selected for Beijing’s First Major Technical Equipment Catalog, according to WeMed, providing a procurement reference point for hospital procurement decisions within the capital. The competitive dynamics of the Chinese PCI robot market — with R-ONE’s established clinical base in Shanghai hospitals and ETcath entering with domestic-origin IP credentials — will develop over 2025 and 2026.
See the Vascular Interventional Robots hub for a category overview of approved platforms in China.